Acta Haematologica Polonica最新文献

英文中文

Hematology on Twitter 推特上的血液学

Q3 Medicine

Acta Haematologica Polonica

Pub Date : 2023-01-27 DOI: 10.5603/ahp.a2023.0002

Tomasz Styczyński, Jagoda Sadlok, J. Styczyński

引用次数: 1

Running up the hill 跑上山

Q3 Medicine

Acta Haematologica Polonica

Pub Date : 2022-12-23 DOI: 10.5603/ahp.2022.0052

J. Styczynski

引用次数: 0

Influence of gut microbiota on efficacy and adverse effects of treatment of lymphoproliferative disorders 肠道菌群对淋巴细胞增生性疾病治疗疗效及不良反应的影响

Q3 Medicine

Acta Haematologica Polonica

Pub Date : 2022-12-23 DOI: 10.5603/ahp.a2022.0053

K. Zielonka, M. Jasiński, K. Jamroziak

引用次数: 0

Coagulopathy and thromboembolism in children with COVID-19 – pathophysiology, thrombotic risk, clinical manifestations and management COVID-19患儿凝血功能障碍和血栓栓塞——病理生理学、血栓形成风险、临床表现和治疗

Q3 Medicine

Acta Haematologica Polonica

Pub Date : 2022-12-23 DOI: 10.5603/ahp.a2022.0054

A. Jabłońska, M. Chmiel, Natalia Chwarścianek, Krzysztof Czyżewski, Monika Richert-Przygonska

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the beginning of the pandemic, it has been generally accepted that children infected with SARS-CoV-2 either stay asymptomatic or present benign symptoms. Yet SARS-CoV-2 is widely known to cause serious consequences in children and adolescents. Complications may develop during infection, several weeks afterwards, or in the course of multisystem inflammatory syndrome in children (MIS-C). MIS-C manifests with fever, gastrointestinal, cardiovascular and/or neurological symptoms. Moreover, thromboembolism is a relatively common complication of COVID-19 and MIS-C. The purpose of this work was to review current reports on thromboembolic complications among children who underwent SARS-CoV-2 infection. Among the published cases of MIS-C, thromboembolic incidents ranged from 1.4% to 6.5%, taking the form of a brain infarct, deep vein thrombosis, pulmonary embolism, or splenic infarct. Several mechanisms leading to thrombosis in COVID-19 in children are considered. The development of acute infection in the lungs results in local clot formation in the pulmonary microcirculation, leading to perfusion disturbances. ADAMTS13 activity is also mildly reduced in patients infected with SARS-CoV-2, increasing the risk of microthrombosis. COVID-19-associated coagulopathy is characterized by elevated D-dimers and fibrinogen levels. Significantly increased D-dimers probably represent activation of coagulation caused by viremia and cytokine storm, as well as possible organ dysfunction. The treatment of thromboembolism in children includes low and high molecular weight heparins and acetylsalicylic acid. Pediatricians should be aware of the possible multiple complications associated with COVID-19 in children, including thromboembolic incidents. Copyright © 2022 Sciendo. All rights reserved.

冠状病毒病2019 (COVID-19)是一种由严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)引起的传染病。自大流行开始以来，人们普遍认为，感染了SARS-CoV-2的儿童要么没有症状，要么出现良性症状。然而，众所周知，SARS-CoV-2会对儿童和青少年造成严重后果。并发症可在感染期间、几周后或在儿童多系统炎症综合征(MIS-C)过程中发生。misc表现为发热、胃肠道、心血管和/或神经系统症状。此外，血栓栓塞是COVID-19和MIS-C相对常见的并发症。这项工作的目的是回顾目前关于接受SARS-CoV-2感染的儿童血栓栓塞并发症的报道。在已发表的MIS-C病例中，血栓栓塞发生率从1.4%到6.5%不等，表现为脑梗死、深静脉血栓形成、肺栓塞或脾梗死。考虑了导致儿童COVID-19血栓形成的几种机制。肺部急性感染的发展导致肺微循环局部凝块形成，导致灌注紊乱。在感染SARS-CoV-2的患者中，ADAMTS13活性也轻度降低，增加了微血栓形成的风险。covid -19相关凝血功能障碍的特征是d -二聚体和纤维蛋白原水平升高。d -二聚体的显著增加可能代表病毒血症和细胞因子风暴引起的凝血激活，以及可能的器官功能障碍。儿童血栓栓塞的治疗包括低分子量和高分子量肝素和乙酰水杨酸。儿科医生应意识到与COVID-19相关的儿童可能出现的多种并发症，包括血栓栓塞事件。版权所有©2022 Sciendo。版权所有。

{"title":"Coagulopathy and thromboembolism in children with COVID-19 – pathophysiology, thrombotic risk, clinical manifestations and management","authors":"A. Jabłońska, M. Chmiel, Natalia Chwarścianek, Krzysztof Czyżewski, Monika Richert-Przygonska","doi":"10.5603/ahp.a2022.0054","DOIUrl":"https://doi.org/10.5603/ahp.a2022.0054","url":null,"abstract":"Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since the beginning of the pandemic, it has been generally accepted that children infected with SARS-CoV-2 either stay asymptomatic or present benign symptoms. Yet SARS-CoV-2 is widely known to cause serious consequences in children and adolescents. Complications may develop during infection, several weeks afterwards, or in the course of multisystem inflammatory syndrome in children (MIS-C). MIS-C manifests with fever, gastrointestinal, cardiovascular and/or neurological symptoms. Moreover, thromboembolism is a relatively common complication of COVID-19 and MIS-C. The purpose of this work was to review current reports on thromboembolic complications among children who underwent SARS-CoV-2 infection. Among the published cases of MIS-C, thromboembolic incidents ranged from 1.4% to 6.5%, taking the form of a brain infarct, deep vein thrombosis, pulmonary embolism, or splenic infarct. Several mechanisms leading to thrombosis in COVID-19 in children are considered. The development of acute infection in the lungs results in local clot formation in the pulmonary microcirculation, leading to perfusion disturbances. ADAMTS13 activity is also mildly reduced in patients infected with SARS-CoV-2, increasing the risk of microthrombosis. COVID-19-associated coagulopathy is characterized by elevated D-dimers and fibrinogen levels. Significantly increased D-dimers probably represent activation of coagulation caused by viremia and cytokine storm, as well as possible organ dysfunction. The treatment of thromboembolism in children includes low and high molecular weight heparins and acetylsalicylic acid. Pediatricians should be aware of the possible multiple complications associated with COVID-19 in children, including thromboembolic incidents. Copyright © 2022 Sciendo. All rights reserved.","PeriodicalId":35805,"journal":{"name":"Acta Haematologica Polonica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44113846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transborder program of allogeneic hematopoietic cell transplantations from unrelated donors for Ukrainian children between 2015–2020 in Bydgoszcz 2015-2020年乌克兰比得哥什非亲属供体异体造血细胞跨境移植项目

Q3 Medicine

Acta Haematologica Polonica

Pub Date : 2022-12-23 DOI: 10.5603/ahp.a2022.2055

J. Styczyński, R. Dębski, Krzysztof Czyżewski, Monika Richert-Przygonska

引用次数: 0

Comparison of depressive, anxiety, and somatic symptoms in patients with essential thrombocythemia, polycythemia vera, and myelofibrosis treated with interferon alpha 干扰素α治疗原发性血小板增多症、真性红细胞增多症和骨髓纤维化患者抑郁、焦虑和躯体症状的比较

Q3 Medicine

Acta Haematologica Polonica

Pub Date : 2022-11-14 DOI: 10.5603/ahp.a2022.0058

Katarzyna Gibek, T. Sacha, K. Cyranka

引用次数: 0

Patient with orbital involvment by mycosis fungoides and COVID-19 真菌样真菌病合并新冠肺炎侵犯眼眶的患者

Q3 Medicine

Acta Haematologica Polonica

Pub Date : 2022-11-07 DOI: 10.5603/ahp.a2022.2057

A. Juda, W. Tomczak, A. Tomczak, Anna Toczek, A. Gerkowicz, D. Krasowska, M. Hus

引用次数: 0

Studies on platelet function during the first year of ibrutinib treatment in patients with chronic lymphocytic leukemia 伊布替尼治疗慢性淋巴细胞白血病第一年血小板功能的研究

Q3 Medicine

Acta Haematologica Polonica

Pub Date : 2022-11-07 DOI: 10.5603/ahp.a2022.2056

B. Sokołowska, D. Jawniak, Aleksandra Nowaczyńska, A. Szymczyk, E. Wąsik-Szczepanek, M. Hus

引用次数: 0

Relationship between thyroid hormone levels in euthyroid patients before HSCT and time to achieve neutrophil and platelet engraftment: an analytical cross-sectional study 甲状腺功能正常患者HSCT前甲状腺激素水平与实现中性粒细胞和血小板植入时间的关系:一项分析性横断面研究

Q3 Medicine

Acta Haematologica Polonica

Pub Date : 2022-11-02 DOI: 10.5603/ahp.a2022.2051

Sepideh Tahsini Tekantapeh, N. Gholami, R. Dolatkhah, Vahideh Sadra, M. Derakhshani, B. Nejati, A. Movassaghpour

引用次数: 0

Receiving of SARS-CoV-2/COVID-19 convalescent plasma in 2020–2021 in context of activity of Regional Center of Blood Donation and Blood Treatment in Bydgoszcz, Poland 在波兰比得哥什地区献血和血液治疗中心的活动背景下，2020年至2021年接受SARS-CoV-2/新冠肺炎恢复期血浆

Q3 Medicine

Acta Haematologica Polonica

Pub Date : 2022-10-31 DOI: 10.5603/ahp.a2022.0043

Katarzyna Gągola

Introduction: We analyzed SARS-CoV-2/COVID-19 convalescent plasma (CCP) production in the process of qualifying donors-convalescents, plasma collection and dispensing from the Regional Center of Blood Donation and Blood Treatment (RCKiK, Regionalne Centrum Krwiodawstwa i Krwiolecznictwa) in Bydgoszcz in the light of Polish national data. Material and methods: This retrospective analysis based on the RCKiK documentation covers the first year of convalescent plasma production and use, i.e. from 1 May 2020 to 30 April 2021. Evaluations of the qualifying process for convalescent donors, plasma collection, and dispensing to hospitals were carried out. The data was analyzed in relation to data from all over Poland provided by the National Blood Center. Results: In the 12 months ending on 30 April, 2021, 121,896.2 CCP units were acquired in total in 21 Regional Blood Donation and Treatment Centers. Of these, 14,683 units (12%) were acquired in Bydgoszcz, which places RCKiK Bydgoszcz in first place in Poland. The majority of donors were men, and most men were multiple donors, but most women were first-time donors. Most donors donated blood once, but 28.8% of donors donated at least twice. Most donations took place between December 2020 and March 2021, i.e. after the peak of the second and during the third wave of the pandemic. Nearly all the CCP preparations were dispensed to 29 hospitals in the Kuyavian-Pomeranian Voivodeship, and about 0.4% to other voivodeships. Conclusions: In the period from 1 May 2020 to 30 April 2021, the RCKiK in Bydgoszcz was the most active center in Poland for obtaining, producing and distributing plasma from people who were convalescing. In the plasma collection process, a very high level of commitment among of RBC personnel and donors was found, expressed in an increased number of donations. A relatively high proportion of donors were first-time and repeat multiple donors, although most donors gave only one donation. The mean anti-SARS-CoV-2 antibodies titer remained at a comparable level up to 150 days after disease. Copyright © 2022 The Polish Society of Haematologists and Transfusiologists, Insitute of Haematology and Transfusion Medicine. All rights reserved.

简介：我们根据波兰国家数据，分析了在符合捐献者资格的过程中，从Bydgoszcz的地区献血和血液治疗中心（RCKiK，Regionalne Centreum Krwiodawstwa i Krwiolecznictwa）采集和分发血浆的过程中SARS-CoV-2/neneneba COVID-19恢复期血浆（CCP）的生产情况。材料和方法：这项基于RCKiK文件的回顾性分析涵盖了恢复期血浆生产和使用的第一年，即2020年5月1日至2021年4月30日。对恢复期捐献者的资格鉴定过程、血浆采集和医院配药进行了评估。这些数据是根据国家血液中心提供的来自波兰各地的数据进行分析的。结果：在截至2021年4月30日的12个月内，21个地区献血和治疗中心共获得121896.2个CCP单位。其中，在Bydgoszcz收购了14683套（12%），使RCKiK Bydgosz在波兰排名第一。大多数捐赠者是男性，大多数男性是多次捐赠者，但大多数女性是首次捐赠者。大多数献血者献血一次，但28.8%的献血者至少献血两次。大多数捐款发生在2020年12月至2021年3月之间，即第二波疫情高峰之后和第三波疫情期间。几乎所有的CCP制剂都分配给了库雅维-波美拉尼亚省的29家医院，约0.4%分配给了其他省。结论：在2020年5月1日至2021年4月30日期间，Bydgoszcz的RCKiK是波兰获取、生产和分发康复者血浆最活跃的中心。在血浆采集过程中，发现加拿大皇家银行人员和捐赠者的承诺水平非常高，捐赠数量增加。尽管大多数捐赠者只捐赠了一次，但第一次和多次捐赠者的比例相对较高。平均抗严重急性呼吸系统综合征冠状病毒2型抗体滴度在发病后150天内保持在可比水平。版权所有©2022波兰血液学家和输血学家学会血液学和输血医学研究所。保留所有权利。

{"title":"Receiving of SARS-CoV-2/COVID-19 convalescent plasma in 2020–2021 in context of activity of Regional Center of Blood Donation and Blood Treatment in Bydgoszcz, Poland","authors":"Katarzyna Gągola","doi":"10.5603/ahp.a2022.0043","DOIUrl":"https://doi.org/10.5603/ahp.a2022.0043","url":null,"abstract":"Introduction: We analyzed SARS-CoV-2/COVID-19 convalescent plasma (CCP) production in the process of qualifying donors-convalescents, plasma collection and dispensing from the Regional Center of Blood Donation and Blood Treatment (RCKiK, Regionalne Centrum Krwiodawstwa i Krwiolecznictwa) in Bydgoszcz in the light of Polish national data. Material and methods: This retrospective analysis based on the RCKiK documentation covers the first year of convalescent plasma production and use, i.e. from 1 May 2020 to 30 April 2021. Evaluations of the qualifying process for convalescent donors, plasma collection, and dispensing to hospitals were carried out. The data was analyzed in relation to data from all over Poland provided by the National Blood Center. Results: In the 12 months ending on 30 April, 2021, 121,896.2 CCP units were acquired in total in 21 Regional Blood Donation and Treatment Centers. Of these, 14,683 units (12%) were acquired in Bydgoszcz, which places RCKiK Bydgoszcz in first place in Poland. The majority of donors were men, and most men were multiple donors, but most women were first-time donors. Most donors donated blood once, but 28.8% of donors donated at least twice. Most donations took place between December 2020 and March 2021, i.e. after the peak of the second and during the third wave of the pandemic. Nearly all the CCP preparations were dispensed to 29 hospitals in the Kuyavian-Pomeranian Voivodeship, and about 0.4% to other voivodeships. Conclusions: In the period from 1 May 2020 to 30 April 2021, the RCKiK in Bydgoszcz was the most active center in Poland for obtaining, producing and distributing plasma from people who were convalescing. In the plasma collection process, a very high level of commitment among of RBC personnel and donors was found, expressed in an increased number of donations. A relatively high proportion of donors were first-time and repeat multiple donors, although most donors gave only one donation. The mean anti-SARS-CoV-2 antibodies titer remained at a comparable level up to 150 days after disease. Copyright © 2022 The Polish Society of Haematologists and Transfusiologists, Insitute of Haematology and Transfusion Medicine. All rights reserved.","PeriodicalId":35805,"journal":{"name":"Acta Haematologica Polonica","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44863407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Acta Haematologica Polonica

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀